Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Doctor training program aims to boost asthma control

NCT ID NCT05440097

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a program that educates doctors on the latest asthma guidelines can improve how they treat patients. About 1500 people with asthma in China took part. The program included training sessions and reminders to help doctors follow best practices. The main goal was to see if more patients would receive the right kind of inhaler treatment after the program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Quality improvement program (guideline education and implementation)
What this could lead to
If successful, this program could show that training doctors on asthma guidelines leads to better treatment and control for patients.
What could go wrong
This is a completed study evaluating a program, not testing a new drug. Results may not apply to other countries or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,500 people

The number who actually took part.

Started

Jul 2022

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be 14 years of age or older at the time of signing the informed consent. 2. Physician-confirmed asthma diagnosis with documented evidence of variable expiratory airflow limitation (e.g. from bronchodilator reversibility testing or other test) 3. Participating patients and/or their legally authorised representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion Criteria: 1. Previous diagnosis of chronic obstructive pulmonary disease (COPD) or other clinically relevant chronic respiratory disease other than asthma 2. Any significant disease or disorder (e.g. cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study 3. Disease or condition other than asthma that requires treatment with systemic or oral steroids 4. Participation in another clinical study with an Investigational Product administered in the last 3 months prior to Visit 1.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Research Site

    Beijing, 100020, China

  • Research Site

    Beijing, 100050, China

  • Research Site

    Beijing, 100080, China

  • Research Site

    Changchun, 130033, China

  • Research Site

    Changsha, 410005, China

  • Research Site

    Changzhi, 046000, China

  • Research Site

    Chengdu, 610021, China

  • Research Site

    Chongqing, 404197, China

  • Research Site

    Dalian, 116011, China

  • Research Site

    Foshan, 528315, China

  • Research Site

    Guangzhou, 510620, China

  • Research Site

    Handan, 056000, China

  • Research Site

    Harbin, 150001, China

  • Research Site

    Hebi, 458000, China

  • Research Site

    Hefei, 230011, China

  • Research Site

    Huai'an, 223000, China

  • Research Site

    Jinan, 250031, China

  • Research Site

    Jinhua, 322100, China

  • Research Site

    Kunming, 650051, China

  • Research Site

    Kunshan, 215316, China

  • Research Site

    Nanchang, 331700, China

  • Research Site

    Nanning, China

  • Research Site

    Ningbo, 315040, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Shanghai, 200080, China

  • Research Site

    Shiyan, 442005, China

  • Research Site

    Taizhou, 317100, China

  • Research Site

    Tianjin, 300450, China

  • Research Site

    Wuhu, 241000, China

  • Research Site

    Wuyishan, 354300, China

  • Research Site

    Xi'an, 710038, China

  • Research Site

    Yantai, 265701, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.